Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

biosimilars

This page shows the latest biosimilars news and features for those working in and with pharma, biotech and healthcare.

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Settlement clears path for Biogen, Samsung’ s Humira biosimilar. Agreement could see Europe access Imraldi as early as October this year. ... Biogen and partner Samsung Bioepis have agreed a deal that will allow their biosimilar version of AbbVie’s

Latest news

More from news
Approximately 124 fully matching, plus 274 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    These declines are driven by the patent expiry of Enbrel and subsequent brand erosion caused by the launch of biosimilars, ”says Annis. ... The rise of biosimilars is likely to present the main challenge to immunology products in 2018, particularly in

  • The tipping point The tipping point

    Driving disparity. If we look across Europe at biosimilar penetration, even the recently launched infliximab and etanercept biosimilars show highly variable uptake between markets. ... Once medical communities are ‘biosimilar experienced’there is

  • Biologic or biosimilar: what are prescribers thinking? Biologic or biosimilar: what are prescribers thinking?

    Biologic or biosimilar: what are prescribers thinking? Biosimilars are raising their competitive game, but are physicians convinced? ... While these external influences on biosimilar uptake are becoming increasingly important, the final decision still

  • Positive disruption in business intelligence Positive disruption in business intelligence

    Earlier this year when Boehringer Ingelheim started a trial on its biosimilar candidate to Abbvie’s Humira, it announced the study in a press release and tweeted: ‘We start a clinical ... study on interchangeability between a biosimilar candidate and

  • Building a bright future Building a bright future

    Savings and increased access have been the billboard claims since the first biosimilar was launched in Europe in 2006. ... It can have almost as large an impact on the total market price as it has on biosimilar/reference product price.’.

More from intelligence
Approximately 11 fully matching, plus 46 partially matching documents found.

Latest appointments

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop

  • PharmaLex appoints Zabin Younes as associate director PharmaLex appoints Zabin Younes as associate director

    She joins the group as an associate director and arrives from ERA Consulting - a biopharmaceutical consultancy based in the UK - where she picked up experience in the biosimilar development lifecycle. ... With experience spanning over 15 years,

  • GW Pharmaceuticals strengthens research and development team GW Pharmaceuticals strengthens research and development team

    Knappertz has previously held several leadership positions including vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva, and numerous clinical and medical roles at Bayer and

  • Sandoz UK promotes Tim de Gavre to country head Sandoz UK promotes Tim de Gavre to country head

    Novartis’generics and biosimilar division Sandoz has appointed Tim de Gavre as its new country head for the UK. ... Our combined portfolio of small molecule generics and biosimilars makes a significant different to medicines costs, and helps the NHS

  • Novimmune expands senior management team Novimmune expands senior management team

    Fleurant joins Novimmune with 20 years of quality expertise in life sciences, most recently having served as head of quality affairs at Alvotech, an Icelandic biosimilars specialist.

More from appointments
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest from PMHub

  • Video: Global Biosimilars Market

    Video: Global Biosimilars Market. Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch. ... It is predicted that

  • Webinar: What next for biosimilars?

    Webinar: What next for biosimilars? Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST. ... Join market research consultants Laurent Chanroux and Richard Head for this complimentary webinar in which they will explore and compare biosimilars in RA and

  • Biosimilars: Getting the flock to market

    The factor that drives the success of biosimilars is value. The biosimilar dividend is that more patients can get access to the high-value treatments they need. ... Luckily, the biosimilar path has already been trodden, so new agents can slipstream the

  • Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

    Free Thinking: Are biosimilars the answer to the rising cost of RA treatment? ... With Enbrel biosimilar Benepali about to launch across EU, we ask what’ s next for RA?

  • Biosimilars: Bringing patients into the conversation

    Biosimilars: Bringing patients into the conversation. Published in eyeforpharma January 2017 by Mariel Metcalfe. ... We looked at physician attitudes to biosimilars and the challenges manufacturers face in gaining widespread acceptance.

More from PMHub
Approximately 14 fully matching, plus 25 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Quick links

Infographics

Multimedia